UBS Group’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-138,241
| Closed | -$3.27M | – | 10301 |
|
|
2023
Q4 | $3.27M | Buy |
138,241
+5,741
| +4% | +$102K | ﹤0.01% | 3258 |
|
|
2023
Q3 | $1.98M | Buy |
132,500
+78,633
| +146% | +$1.04M | ﹤0.01% | 3446 |
|
|
2023
Q2 | $590K | Sell |
53,867
-15,933
| -23% | -$148K | ﹤0.01% | 4685 |
|
|
2023
Q1 | $609K | Sell |
69,800
-215,936
| -76% | -$1.73M | ﹤0.01% | 4543 |
|
|
2022
Q4 | $1.79M | Sell |
285,736
-209,502
| -42% | -$796K | ﹤0.01% | 3495 |
|
|
2022
Q3 | $1.73M | Buy |
495,238
+39,973
| +9% | +$144K | ﹤0.01% | 3285 |
|
|
2022
Q2 | $1.34M | Buy |
455,265
+423,806
| +1,347% | +$1.01M | ﹤0.01% | 3473 |
|
|
2022
Q1 | $99K | Sell |
31,459
-25,683
| -45% | -$80.8K | ﹤0.01% | 5929 |
|
|
2021
Q4 | $193K | Buy |
57,142
+25,345
| +80% | +$96.2K | ﹤0.01% | 5737 |
|
|
2021
Q3 | $116K | Sell |
31,797
-4,684
| -13% | -$18.5K | ﹤0.01% | 5733 |
|
|
2021
Q2 | $159K | Sell |
36,481
-82,889
| -69% | -$367K | ﹤0.01% | 5526 |
|
|
2021
Q1 | $542K | Sell |
119,370
-9,574
| -7% | -$51.5K | ﹤0.01% | 4800 |
|
|
2020
Q4 | $740K | Buy |
128,944
+92,874
| +257% | +$703K | ﹤0.01% | 4263 |
|
|
2020
Q3 | $261K | Sell |
36,070
-342,797
| -90% | -$1.83M | ﹤0.01% | 4632 |
|
|
2020
Q2 | $1.32M | Buy |
378,867
+6,965
| +2% | +$20.1K | ﹤0.01% | 3272 |
|
|
2020
Q1 | $551K | Buy |
371,902
+287,393
| +340% | +$483K | ﹤0.01% | 3871 |
|
|
2019
Q4 | $166K | Sell |
84,509
-73,877
| -47% | -$277K | ﹤0.01% | 5720 |
|
|
2019
Q3 | $811K | Buy |
158,386
+83,586
| +112% | +$506K | ﹤0.01% | 4150 |
|
|
2019
Q2 | $536K | Sell |
74,800
-6,176
| -8% | -$69.9K | ﹤0.01% | 4245 |
|
|
2019
Q1 | $1.07M | Buy |
80,976
+45,859
| +131% | +$488K | ﹤0.01% | 3525 |
|
|
2018
Q4 | $276K | Sell |
35,117
-20,835
| -37% | -$198K | ﹤0.01% | 4702 |
|
|
2018
Q3 | $620K | Sell |
55,952
-85,629
| -60% | -$1.06M | ﹤0.01% | 4265 |
|
|
2018
Q2 | $1.9M | Buy |
141,581
+109,349
| +339% | +$1.37M | ﹤0.01% | 3223 |
|
|
2018
Q1 | $419K | Buy |
32,232
+23,562
| +272% | +$293K | ﹤0.01% | 4325 |
|
|
2017
Q4 | $80K | Buy |
8,670
+5,670
| +189% | +$48.5K | ﹤0.01% | 5518 |
|
|
2017
Q3 | $24K | Sell |
3,000
-1,738
| -37% | -$11.8K | ﹤0.01% | 6330 |
|
|
2017
Q2 | $27K | Buy |
4,738
+979
| +26% | +$4.17K | ﹤0.01% | 6085 |
|
|
2017
Q1 | $16K | Sell |
3,759
-3,310
| -47% | -$9.49K | ﹤0.01% | 6323 |
|
|
2016
Q4 | $12K | Buy |
7,069
+4,069
| +136% | +$7.18K | ﹤0.01% | 6832 |
|
|
2016
Q3 | $6K | Sell |
3,000
-3,128
| -51% | -$6.22K | ﹤0.01% | 7071 |
|
|
2016
Q2 | $10K | Buy |
+6,128
| New | +$12.7K | ﹤0.01% | 6800 |
|
|
2015
Q3 | – | Sell |
-6,771
| Closed | -$18K | – | 8708 |
|
|
2015
Q2 | $18K | Buy |
+6,771
| New | +$27.8K | ﹤0.01% | 6987 |
|
|
2015
Q1 | – | Sell |
-329
| Closed | -$3K | – | 9521 |
|
|
2014
Q4 | $3K | Buy |
+329
| New | +$2.65K | ﹤0.01% | 9287 |
|
Other funds holding CBAY
UBS Group's CBAY Position: Q1 2024 in Review
UBS Group sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 138,241 shares — an estimated $3.27M sold.
UBS Group first reported a position in CBAY in Q4 2014 and held it in 33 quarters. The position peaked at $3.27M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- UBS Group reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- UBS Group sold 138,241 Cymabay Therapeutics shares in Q1 2024, an estimated $3.27M.
- UBS Group first reported a position in Cymabay Therapeutics in Q4 2014 and held it in 33 quarters.
- UBS Group's Cymabay Therapeutics position peaked at $3.27M in Q4 2023.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.